|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
gptkb:pertuzumab
chemotherapy
intravenous infusion
docetaxel
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XC03
|
|
gptkbp:biosimilar
|
true
|
|
gptkbp:CASNumber
|
180288-69-1
|
|
gptkbp:chemicalFormula
|
C6470H10012N1724O2013S42
|
|
gptkbp:contraindication
|
pregnancy
hypersensitivity to trastuzumab
|
|
gptkbp:developedBy
|
gptkb:Genentech
|
|
gptkbp:discoveredBy
|
gptkb:Dennis_Slamon
|
|
gptkbp:firstApprovedIndication
|
HER2-positive metastatic breast cancer
|
|
gptkbp:form
|
solution for injection
lyophilized powder
|
|
gptkbp:genericName
|
gptkb:trastuzumab
|
|
gptkbp:halfLife
|
5-12 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Herceptin
|
|
gptkbp:indication
|
HER2-positive early breast cancer
HER2-positive gastroesophageal junction cancer
HER2-positive metastatic gastric cancer
|
|
gptkbp:KEGGID
|
D08141
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Roche
|
|
gptkbp:mechanismOfAction
|
binds to HER2 receptor
inhibits proliferation of HER2-positive cells
|
|
gptkbp:MedlinePlusID
|
a697014
|
|
gptkbp:monitors
|
gptkb:MUGA_scan
echocardiogram
|
|
gptkbp:origin
|
humanized monoclonal antibody
|
|
gptkbp:patentExpired
|
true
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:prescribes
|
oncologist
|
|
gptkbp:product
|
gptkb:IgG1_kappa
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201585
123631
DB00072
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
pulmonary toxicity
cardiotoxicity
infusion reactions
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:target
|
gptkb:HER2_receptor
|
|
gptkbp:UNII
|
P188ANX8CK
|
|
gptkbp:usedFor
|
gptkb:cancer
gastric cancer
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Genentech
|
|
gptkbp:bfsLayer
|
5
|